Vaccines for Staphylococcus aureus and Target Populations
Authors:
- 1 January 2016
- book chapter
- Published by Springer Nature
- Vol. 409, 491-528
Abstract
Staphylococcus aureus is a leading pathogen in surgical site, intensive care unit, and skin infections, as well as healthcare-associated pneumonias. These infections are associated with an enormous burden of morbidity, mortality, and increase of hospital length of stay and patient cost. S. aureus is impressively fast in acquiring antibiotic resistance, and multidrug-resistant strains are a serious threat to human health. Due to resistance or insufficient effectiveness, antibiotics and bundle measures leave a tremendous unmet medical need worldwide. There are no licensed vaccines on the market despite the significant efforts done by public and private initiatives. Indeed, vaccines tested in clinical trials in the last two decades have failed to show efficacy. However, they targeted single antigens and contained no adjuvants and efficacy trials were performed in severely ill subjects. Herein, we provide a comprehensive evaluation of potential target populations for efficacy trials taking into account key factors such as population size, incidence of S. aureus infection, disease outcome, primary endpoints, as well as practical advantages and disadvantages. We describe the whole-blood assay as a potential surrogate of protection, and we show the link between phase III clinical trial data of failed vaccines with their preclinical observations. Finally, we give our perspective on how new vaccine formulations and clinical development approaches may lead to successful S. aureus vaccines.Keywords
This publication has 138 references indexed in Scilit:
- The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patientsVaccine, 2012
- A minimally invasive approach is more cost-effective than a traditional sternotomy approach for mitral valve surgeryThe Journal of Thoracic and Cardiovascular Surgery, 2011
- Molecular differentiation of historic phage-type 80/81 and contemporary epidemic Staphylococcus aureusProceedings of the National Academy of Sciences, 2011
- A Staphylococcus aureus pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in miceNature Medicine, 2011
- Unique Heme-Iron Coordination by the Hemoglobin Receptor IsdB of Staphylococcus aureusBiochemistry, 2011
- Role of a disintegrin and metalloprotease 10 in Staphylococcus aureus α-hemolysin–mediated cellular injuryProceedings of the National Academy of Sciences, 2010
- Staphylococcus aureus vaccine for orthopedic patients: An economic model and analysisVaccine, 2010
- Waves of resistance: Staphylococcus aureus in the antibiotic eraNature Reviews Microbiology, 2009
- Infection Associated with Prosthetic JointsNew England Journal of Medicine, 2009
- Vaccine assembly from surface proteins ofStaphylococcus aureusProceedings of the National Academy of Sciences, 2006